Suppr超能文献

前激肽释放酶和激肽原的检测方法及其应用。

Assay methods for prekallikrein and kininogens and their applications.

作者信息

Uchida Y, Ohishi S, Tanaka K, Harada Y, Ueno A, Katori M, Funahashi S, Hashimoto T, Ueno T, Kodama J

出版信息

Adv Exp Med Biol. 1979;120A:173-84. doi: 10.1007/978-1-4757-0926-1_17.

Abstract

Prekallikrein activity in plasma was assayed using a synthetic peptidyl fluorogenic substrate (carbobenzoxy-L-phenylalanyl-L-arginine 4-methylcoumarinyl-7-amide), after activation of prekallikrein by acetone and kaolin. For total kininogen assay, the pretreatment of plasma at pH 2.0 was the best to eliminate bradykinin potentiators and kininase activity, before addition of trypsin to convert kininogen to bradykinin. Assay method of high molecular weight (HMW) kininogen was established by conversion of HMW-kininogen to bradykinin through activation of Hageman factor by glass powder and that of low molecular weight (LMW) kininogen was also by treatment of HMW-kininogen-depleted plasma in the same way as that for total kininogen. The marked reduction of prekallikrein and HMW-kininogen, not of LMW-kininogen, was found in pleural fluid of rat carrageenin pleurisy, and in plasma after i.v. injection of bromelain in rats. Members of the pedigree of hereditary angioneurotic edema patients also show low levels of prekallikrein and kininogens in plasma.

摘要

在通过丙酮和高岭土激活前激肽释放酶后,使用合成肽基荧光底物(苄氧羰基-L-苯丙氨酰-L-精氨酸4-甲基香豆素-7-酰胺)测定血浆中的前激肽释放酶活性。对于总激肽原测定,在加入胰蛋白酶将激肽原转化为缓激肽之前,将血浆在pH 2.0下进行预处理是消除缓激肽增强剂和激肽酶活性的最佳方法。通过玻璃粉激活Hageman因子将高分子量(HMW)激肽原转化为缓激肽来建立HMW激肽原的测定方法,低分子量(LMW)激肽原的测定方法也是通过以与总激肽原相同的方式处理去除HMW激肽原的血浆来进行。在大鼠角叉菜胶性胸膜炎的胸腔积液以及大鼠静脉注射菠萝蛋白酶后的血浆中,发现前激肽释放酶和HMW激肽原显著减少,而LMW激肽原未减少。遗传性血管性水肿患者家系中的成员血浆中的前激肽释放酶和激肽原水平也较低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验